Researchers at the NIAID launched a phase 3 multicenter trial of an experimental shingles vaccine. The vaccine is a more potent version of the chickenpox vaccine already in use to prevent varicella zoster virus (VZV) infection in children.
Researchers believe that the vaccine may be able to prevent shingles by boosting the body's immune response to VZV infection in a person who had chickenpox in childhood. The national trial, which will involve some 20 medical centers, is recruiting 37,000 volunteers. To be eligible for the trial, participants must be age 60 or older, have had chickenpox, have never had shingles, and be in good general health. For further information about the trial, call (800) 772-5464, ext 658.
Stephenson J. Shingles Vaccine Trial. JAMA. 1999;282(7):625. doi:10.1001/jama.282.7.625-JHA90006-4-1